1. Scrip
  2. >>Business
  3. >>Strategy

Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets

 
• By Sten Stovall

Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.

Klebsiella
AMRC Will Develop Compounds From Medivir’s Anti-Superbug MBLI Program • Source: Shutterstock

Sweden-based Medivir – which in October 2016 decided to only focus on oncology R&D – is divesting its research stage metallo-β-lactamase inhibitor (MBLI) program to the UK's AMR Centre Ltd in return for a proportion of future sales from antimicrobials produced.

The MBLI program is aimed at tackling the threat posed by NDM-1 and other metallo-β-lactamases, enzymes that make bacteria resistant to widely used beta-lactam antibiotics such as penicillin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.